Pitt Street Research | Stock research

Imagion Biosystems

Imagion Biosystem’s revolutionary MagSense imaging technology is potentially orders of magnitude more effective than CT and MRI at detecting cancer. MagSense was granted Breakthrough Device status by the FDA in June 2019 and is currently being prepared for its first clinical study, potentially in Her2-positive breast cancer.

Imagion Biosystems (ASX:IBX)

 

Imagion Biosystems’ (ASX:IBX) revolutionary MagSense imaging technology is potentially orders of magnitude more effective than CT and MRI at detecting cancer. MagSense was granted Breakthrough Device status by the FDA in June 2019 and is currently being prepared for its first clinical study, potentially in Her2-positive breast cancer.